
    
      To improve cytogenetic and molecular response of CML patients receiving Imatinib, who have
      not achieved an optimal response according to European LeukemiaNet (ELN) definitions , or MR4
      after 24 months with Imatinib. This will be achieved by addition of the CXCR4 antagonist
      BL-8040, mobilizing CML leukemia stem cells from their protective bone marrow niche and
      exposing them to Imatinib and BL-8040-mediated apoptosis.
    
  